AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

755.666

+7.7451.04%

Number of Gainers:17

Number of Losers:12

Number of Flat:16

PE:- -

High:756.356

Open:753.505

Low:749.555

Close:747.921

Volume:43.52M

Turnover:201.05M

Market Cap:114.75B

Float Cap:111.15B

Loading ...

Opthea Limited Secures A$10.8 Million Australian R&D Tax Incentive to Advance Sozinibercept Development

Immuron Extends At-the-Market Funding Facility to Aggregate Offering Price of Around $2.8 Million

MT Newswires Live

Why Mesoblast (ASX:MSB) Is Up 15.0% After Securing US Medicare J-Code for Ryoncil

Simply Wall St.

ASX Stocks That May Be Undervalued In October 2025

Simply Wall St.

ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems

Simply Wall St.

Race Oncology (ASX:RAC): Evaluating Valuation After Breakthrough Discovery in Cancer Therapy Mechanism

Simply Wall St.

Coinbase Applies to OCC for National Trust Charter

An Insider At Imricor Medical Systems Lowered Their Holding Recently

Simply Wall St.

Mesoblast (ASX:MSB): Assessing Valuation After Ryoncil Wins Permanent U.S. J-Code for Reimbursement

Simply Wall St.

Weekly Wrap: Will the ASX 200 Break Records? Investors Hope for Continued Momentum

Immuron Limited Announces Increase of At-the-Market Offering Program by $2.85 Million

Shares of Immuron Rise as Reports No Impact From US Tariffs

MT Newswires Live

BUZZ-ASX-listed Mesoblast surges on US Medicare billing approval for key drug

Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says

MT Newswires Live

OncoSil Medical Begins Commercial Operations in Portugal with First Patient Treatment

MT Newswires Live

Canaan Says US-Based Bitcoin Miner Orders Over 50,000 Mining Machines; Shares Rise

MT Newswires Live

Immuron Limited Publishes Shareholder Letter Covering Fiscal Year Ending June 30, 2025

Immuron Limited Announces Planned IND Submission to FDA for IMM-529 Targeting C. difficile Infection, Paving Way for Phase 2 Clinical Trials

Immuron Letter to Shareholders – Projects Update

THOMSON REUTERS

Australian shares climb as gold rally boosts miners

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":755.666,"timestamp":1760072399855,"preClose":747.92145,"halted":0,"volume":43515793,"delay":0,"changeRate":0.010355,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":7.744568,"latestTime":"10-10 16:00:00 AEDT","open":753.5048,"high":756.3559,"low":749.5553,"amount":201050700,"amplitude":0.009093,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1760310000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1760050800000,1760072400000]],"turnoverRate":0.001558,"increases":13,"decrements":13,"flats":17,"marketCap":114748171758,"floatMarketCap":111152797876.5625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":756.3559,"amplitude":0.009093,"preClose":747.92145,"low":749.5553,"latestPrice":755.666,"volume":43515793,"delay":0,"open":753.5048,"prevYearClose":936.801,"prevWeekClose":749.725,"prevMonthClose":712.826,"prevQuarterClose":712.826,"fiveDayClose":749.725,"twentyDayClose":740.889,"sixtyDayClose":876.9,"secType":"PLATE","market":"AU","turnoverRate":0.001558,"marketCap":114748171758,"floatMarketCap":111152797876.5625,"timestamp":1760072399855,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":17,"down":12,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2573675674","title":"Opthea Limited Secures A$10.8 Million Australian R&D Tax Incentive to Advance Sozinibercept Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2573675674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573675674?lang=en_us&edition=fundamental","pubTime":"2025-10-06 18:03","pubTimestamp":1759744987,"startTime":"0","endTime":"0","summary":"Opthea Limited  has announced the receipt of an A$10.8 million  research and development (R&D) tax incentive from the Australian Taxation Office. The incentive, awarded under the Australian Federal Government's R&D Tax Incentive program, supports eligible R&D expenditure for the 2024/2025 financial year, including both Australian and overseas costs related to the development of Opthea's lead candidate, sozinibercept. The funding is exclusive to Opthea Limited and is designed to encourage innovation and advance the company's clinical pipeline. Opthea's Executive Chairman, Jeremy Levin, highlighted the importance of the program in supporting the company's strategic initiatives and reaffirmed a commitment to fiscal discipline while advancing therapeutic development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL2yZcYK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OPT.AU"],"gpt_icon":0},{"id":"2573621008","title":"Immuron Extends At-the-Market Funding Facility to Aggregate Offering Price of Around $2.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2573621008","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573621008?lang=en_us&edition=fundamental","pubTime":"2025-10-06 14:29","pubTimestamp":1759732150,"startTime":"0","endTime":"0","summary":"Immuron  lodged an at-the-market supplementary prospectus with the United States Securities and Exchange Commission, extending the at-the-market funding facility with H.C. Wainwright to an additional aggregate offering price of around $2.8 million, according to a Monday Australian bourse filing.Immuron will control major aspects of the funding, having sole discretion as to whether the firm uses the at-the-market facility, the number of American depository shares issued, as well as the minimum issue price of the American depository shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2573459106","title":"Why Mesoblast (ASX:MSB) Is Up 15.0% After Securing US Medicare J-Code for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2573459106","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573459106?lang=en_us&edition=fundamental","pubTime":"2025-10-06 04:12","pubTimestamp":1759695151,"startTime":"0","endTime":"0","summary":"Mesoblast Limited announced that the permanent Medicare and Medicaid J-Code J3402 for Ryoncil® became active for billing and reimbursement on October 1, 2025, creating a standardized pathway for US healthcare providers.\nThis formal CMS recognition is expected to streamline access and reimbursement, potentially broadening patient reach for the only FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease.\nWe'll now explore how this...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-150-after-securing-us-medicare-j","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-150-after-securing-us-medicare-j","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK7067","BK4006","BK7508","MSB","BK7501"],"gpt_icon":0},{"id":"2573645996","title":"ASX Stocks That May Be Undervalued In October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573645996","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573645996?lang=en_us&edition=fundamental","pubTime":"2025-10-06 03:04","pubTimestamp":1759691067,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a slight pullback following a bullish surge, investors are keenly observing the ASX 200's movements amidst fluctuating global economic factors such as U.S. government shutdown concerns and rising gold prices. In this context, identifying undervalued stocks can be particularly appealing, as they may offer potential opportunities for growth in a market that is currently experiencing volatility and consolidation.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-nic/nickel-industries-shares/news/asx-stocks-that-may-be-undervalued-in-october-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-nic/nickel-industries-shares/news/asx-stocks-that-may-be-undervalued-in-october-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7095","ART.AU","CSX.AU","BK7123","CYP.AU","BK7508","CCR.AU","ELD.AU","RKN.AU","BK7505","NWH.AU","BK7002","NIC.AU","IFM.AU","BK7007","BK7015","RMC.AU","BK7055","BK7501","SLC.AU","BK7503","BK7016","BK7117","BK7160","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2573264599","title":"ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems","url":"https://stock-news.laohu8.com/highlight/detail?id=2573264599","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573264599?lang=en_us&edition=fundamental","pubTime":"2025-10-06 03:02","pubTimestamp":1759690922,"startTime":"0","endTime":"0","summary":"Australian shares are showing signs of consolidation after a recent bullish surge, with the ASX 200 futures indicating a slight decline. Amid such market dynamics, investors often seek opportunities in lesser-known areas like penny stocks, which can still offer growth potential despite their niche status. These smaller or newer companies may present surprising value and stability, making them worth exploring for those interested in diversifying their portfolios.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-dxb/dimerix-shares/news/asx-penny-stocks-spotlight-dimerix-and-two-more-hidden-gems","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-dxb/dimerix-shares/news/asx-penny-stocks-spotlight-dimerix-and-two-more-hidden-gems","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","WAF.AU","BK7055","EZZ.AU","CUP.AU","BK7050","PPL.AU","BK7128","XJO.AU","MTO.AU","BK7062","BK7005","BK7061","BK7508","DXB.AU","BK7007","BK7506","XKO.AU","AAL.AU","SSM.AU","BK7045","BK7048","BK7501","BK7067","PPS.AU","BK7162","DSK.AU","SOM.AU","IGL.AU","BK7503","BK7143","BK7104","BK7077","XAO.AU"],"gpt_icon":0},{"id":"2573660905","title":"Race Oncology (ASX:RAC): Evaluating Valuation After Breakthrough Discovery in Cancer Therapy Mechanism","url":"https://stock-news.laohu8.com/highlight/detail?id=2573660905","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573660905?lang=en_us&edition=fundamental","pubTime":"2025-10-05 02:20","pubTimestamp":1759602017,"startTime":"0","endTime":"0","summary":"Race Oncology (ASX:RAC) is drawing fresh attention after revealing a breakthrough discovery on how its leading drug, bisantrene, fights cancer. This scientific milestone highlights new prospects for targeted therapies and business growth.\nSee our latest analysis for Race Oncology.\nFollowing the news of this breakthrough, Race Oncology shares saw strong momentum, briefly surging nearly 30% over the week. While recent excitement has moderated, the company’s total shareholder return of over 1%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/race-oncology-asxrac-evaluating-valuation-after-breakthrough","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rac/race-oncology-shares/news/race-oncology-asxrac-evaluating-valuation-after-breakthrough","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAC","BK7508","BK7067","RAC.AU"],"gpt_icon":0},{"id":"2572056632","title":"Coinbase Applies to OCC for National Trust Charter","url":"https://stock-news.laohu8.com/highlight/detail?id=2572056632","media":"Blockbeats","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572056632?lang=en_us&edition=fundamental","pubTime":"2025-10-04 08:28","pubTimestamp":1759537680,"startTime":"0","endTime":"0","summary":"BlockBeats News, October 4th, according to The Block, cryptocurrency exchange Coinbase  stated in a declaration that it is applying for a nationwide trust charter with the Office of the Comptroller of the Currency .Greg Tusar, Coinbase's VP of Institutional Products, stated in the declaration: \"The OCC charter will streamline regulatory oversight of new products and foster ongoing innovation, integrating digital assets into traditional finance. We are not the first cryptocurrency company to apply for a federal charter, nor will we be the last.\" Tusar mentioned that Coinbase has no intention of becoming a bank. So far, Paxos, BitGo, Ripple, and Circle have also applied to the OCC for a banking charter in response to the crypto-friendly regulatory environment under the Trump administration.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/314980","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/314980","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["LU1861559042.SGD","BK4539","BK4112","LU2360107671.USD","OCC.AU","LU1861217088.USD","BK4534","LU0130103400.USD","LU0070302665.USD","BK4600","COIN","LU0980610538.SGD","LU0648000940.SGD","LU0289960550.SGD","LU0208291251.USD","LU0211331839.USD","BK4554","BK4020","BK4596","BK4595","LU0130518102.USD","NHLD","LU0477156797.USD","BK4551","LU0320765489.SGD","LU1201861249.SGD","OCC","BK4585","BK4535","LU1861220207.SGD","BK7508","BK4100","CHTR","LU1201861165.SGD","LU0130102774.USD","LU0477156953.USD","BK4588","BK7067","LU0130517989.USD","LU1861558580.USD","LU0175139822.USD","BK4559","BK4516","LU0648001328.SGD"],"gpt_icon":1},{"id":"2572630005","title":"An Insider At Imricor Medical Systems Lowered Their Holding Recently","url":"https://stock-news.laohu8.com/highlight/detail?id=2572630005","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572630005?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:27","pubTimestamp":1759523268,"startTime":"0","endTime":"0","summary":"Viewing insider transactions for Imricor Medical Systems, Inc.'s ( ASX:IMR ) over the last year, we see that insiders...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-imr/imricor-medical-systems-shares/news/an-insider-at-imricor-medical-systems-lowered-their-holding","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-imr/imricor-medical-systems-shares/news/an-insider-at-imricor-medical-systems-lowered-their-holding","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMR.AU","BK7503","BK7508","BK7007"],"gpt_icon":0},{"id":"2572639689","title":"Mesoblast (ASX:MSB): Assessing Valuation After Ryoncil Wins Permanent U.S. J-Code for Reimbursement","url":"https://stock-news.laohu8.com/highlight/detail?id=2572639689","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572639689?lang=en_us&edition=fundamental","pubTime":"2025-10-04 02:32","pubTimestamp":1759516333,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) drew investor attention after announcing that its product, Ryoncil, was granted a permanent J-Code by the U.S. Medicare & Medicaid Services for billing and reimbursement beginning in October 2025.\nSee our latest analysis for Mesoblast.\nMomentum around Mesoblast has picked up following the news about Ryoncil’s new billing code and its designation as a U.S.-origin product, making reimbursement and commercial pathways much clearer for the company. While its short-term share...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-assessing-valuation-after-ryoncil-wins-perm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-assessing-valuation-after-ryoncil-wins-perm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7508","MSB.AU","BK7501","DCF","BK4006","BK7067"],"gpt_icon":0},{"id":"2572555996","title":"Weekly Wrap: Will the ASX 200 Break Records? Investors Hope for Continued Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2572555996","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572555996?lang=en_us&edition=fundamental","pubTime":"2025-10-03 22:06","pubTimestamp":1759500367,"startTime":"0","endTime":"0","summary":"The Australian share market overcame a poor start to rise and salutes the end of the week on Friday, well within reach of record highs.A broad rally in sectors such as healthcare, IT, consumer discretionary and real estate stocks helped to overcome weakness in energy and utilities, helping the ASX 200 to rise by 0.5% or 41.5 points to close at 8987.4 points.That is not far off the record close of 9019.2 points set in August – a level that could be eclipsed in the coming week if the positive trend continues.There is a chance of that as investors continue to see signs of profit growth locally and offshore, with the chance of interest rate cuts coming down the track.Although there is plenty to worry about as well, with the United States once again “enjoying” another public service shutdown of unknown duration and no shortage of doomsayers warning of an AI investment overshoot and rising unemployment.It was a good day too for shareholders in Mesoblast  as the stock added 8.7% t","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/featured-1759499950581.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/featured-1759499950581.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/will-the-asx-200-break-records-investors-hope-for-continued-momentum/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/will-the-asx-200-break-records-investors-hope-for-continued-momentum/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7061","BK7501","360.AU","WDS.AU","BK7511","BK7158","BK7508","CSL.AU","RMS.AU","BK7142","BK4211","BK7094","BK7007","MSB.AU","DGT.AU","EVN.AU","BK7136","XYZ.AU","BK7507","BK7067","BK7042","RHC.AU","NST.AU","PME.AU","TLS.AU","BK7166","HOPE","AGL.AU","BK7506","BK7016","RMD.AU","APE.AU","BK7143","STO.AU","ISBC","APX.AU","BK7503","BK7104","BK7113"],"gpt_icon":0},{"id":"2572838176","title":"Immuron Limited Announces Increase of At-the-Market Offering Program by $2.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2572838176","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572838176?lang=en_us&edition=fundamental","pubTime":"2025-10-03 21:57","pubTimestamp":1759499865,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced an increase to its at-the-market  offering program with H.C. Wainwright & Co., LLC, allowing the company to offer and sell additional American Depositary Shares  representing its ordinary shares. The maximum aggregate offering price under the ATM Agreement has been increased by approximately $2.85 million. The ADSs will be issued and sold from time to time at Immuron's discretion, with proceeds intended to support the company's ongoing operations and growth initiatives. Sales will be conducted pursuant to the company's effective shelf registration statement on Form F-3 and related prospectus.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL9T2DBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2572576704","title":"Shares of Immuron Rise as Reports No Impact From US Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2572576704","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572576704?lang=en_us&edition=fundamental","pubTime":"2025-10-03 12:35","pubTimestamp":1759466135,"startTime":"0","endTime":"0","summary":"Shares of Immuron  rose past 8% in recent Friday trade after it said late Thursday that it expects no material impact from the newly introduced US tariffs on pharmaceutical products.In the same statement, the company said top-line results from the clinical study of IMM-124E, or Travelan, for traveler's diarrhea will be released this month, advancing toward US Food and Drug Administration  phase 3 trials.In addition, the company said it plans to submit an application with the US FDA by mid-October to advance IMM-529 into phase 2 trials for Clostridioides difficile infection, an infection of the colon caused by the Clostridioides difficile bacteria.The company is fast-tracking a limited launch in Australia of ProIBS for irritable bowel syndrome in the fourth quarter, with a full rollout targeted for 2026. IMM-986, developed with Monash University, starts pre-clinical studies by year-end to tackle antimicrobial resistance, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2572828520","title":"BUZZ-ASX-listed Mesoblast surges on US Medicare billing approval for key drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2572828520","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572828520?lang=en_us&edition=fundamental","pubTime":"2025-10-03 09:37","pubTimestamp":1759455452,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Mesoblast surges on US Medicare billing approval for key drug** Shares of Mesoblast MSB.AX advance as much as 16.9% to A$2.970, their highest since February 13** Second-best performer ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nL6N3VK029:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2572631522","title":"Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2572631522","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572631522?lang=en_us&edition=fundamental","pubTime":"2025-10-03 08:34","pubTimestamp":1759451674,"startTime":"0","endTime":"0","summary":"Orthocell's  record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2572521266","title":"OncoSil Medical Begins Commercial Operations in Portugal with First Patient Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2572521266","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572521266?lang=en_us&edition=fundamental","pubTime":"2025-10-03 07:35","pubTimestamp":1759448150,"startTime":"0","endTime":"0","summary":"OncoSil Medical  has commenced its commercial rollout in Portugal with the successful first treatment using the OncoSil device at Instituto Portugues de Oncologia do Porto Francisco Gentil on Oct. 2, according to a Friday filing with the Australian bourse.The company will continue partnering with clinicians in Portugal to support OncoSil adoption and expand into new international markets, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","BK7508","OSL.AU"],"gpt_icon":0},{"id":"2572510106","title":"Canaan Says US-Based Bitcoin Miner Orders Over 50,000 Mining Machines; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2572510106","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572510106?lang=en_us&edition=fundamental","pubTime":"2025-10-02 21:39","pubTimestamp":1759412353,"startTime":"0","endTime":"0","summary":"Canaan  said Thursday that a US-based bitcoin miner has ordered more than 50,000 of its Avalon A15 Pro mining machines.The company said the order is the largest in the past three years and is set to be delivered in Q4.Canaan shares were up 19% in recent trading.Price: 1.23, Change: +0.19, Percent Change: +17.98","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09008","83042","BK1611","BK4601","BK7502","BK4600","03042","BK7096","BK4585","BK4526","09042","BK4170","CAN.AU","MBTmain","BK7508","CAN","09439","BK4588","BK4595","BK4594"],"gpt_icon":0},{"id":"2572515985","title":"Immuron Limited Publishes Shareholder Letter Covering Fiscal Year Ending June 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2572515985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572515985?lang=en_us&edition=fundamental","pubTime":"2025-10-02 18:06","pubTimestamp":1759399610,"startTime":"0","endTime":"0","summary":"Immuron Limited has released a shareholder letter outlining several updates. The company does not expect any material impact from recent US tariffs on pharmaceutical products. Topline results from the Travelan clinical study conducted by Uniformed Services University are anticipated in October 2025. An Investigational New Drug  application for IMM-529, targeting Clostridioides difficile infection, is planned for submission to the U.S. FDA in mid-October 2025. The Australian commercial launch of ProIBS is scheduled for the fourth quarter of 2025, with a full launch expected in the first quarter of 2026. Initial pre-clinical research studies for IMM-986, targeting Vancomycin-resistant Enterococci, are expected to be completed by the end of 2025. The full letter can be accessed through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL3GsVPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2572251530","title":"Immuron Limited Announces Planned IND Submission to FDA for IMM-529 Targeting C. difficile Infection, Paving Way for Phase 2 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2572251530","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572251530?lang=en_us&edition=fundamental","pubTime":"2025-10-02 18:00","pubTimestamp":1759399214,"startTime":"0","endTime":"0","summary":"Immuron Limited Announces Planned IND Submission to FDA for IMM-529 Targeting C. difficile Infection, Paving Way for Phase 2 Clinical Trials. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire  on October 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL7q19xD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IE00BGHQF748.EUR","LU2210150020.SGD","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IMC.AU","LU2210149790.SGD","BK4112","BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK7067","BK4585","NDAQ"],"gpt_icon":0},{"id":"2572515354","title":"Immuron Letter to Shareholders – Projects Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2572515354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572515354?lang=en_us&edition=fundamental","pubTime":"2025-10-02 18:00","pubTimestamp":1759399200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nTUA2ZXSS4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2572597125","title":"Australian shares climb as gold rally boosts miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2572597125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572597125?lang=en_us&edition=fundamental","pubTime":"2025-10-02 16:12","pubTimestamp":1759392728,"startTime":"0","endTime":"0","summary":"Australian shares climb as gold rally boosts minersGold rally lifts mining sub-index to 2-1/2-year highHealthcare stocks rise, following Wall Street's leadMajor banks rise, supported by RBA's stability reviewUpdates to closeBy Roushni Nair and Jasmeen Ara Islam Shaikh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"3090b0aeeb709a311d676904c789c8fe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nL3N3VJ0ET:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXL.AU","NEU.AU","LTR.AU","BK7501","BK7096","BK7508","BK7511","BHP.AU","CSL.AU","BK7095","BK7104","BK7507","BK7067","OBM.AU","MSB.AU","BK7504"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":110,"code":"91000000","status":"200"}]}}